Verhoef, T.I.

patient study warfarin coumarin dosing pharmacogenetic therapy cyp 2c vkorc genotyping genotype treatment anticoagulation event month trial coumarin derivatives acenocoumarol group –effectivenes university range result health anticoagulant cost –effectiveness vkorc 1 atrial fibrillation fi rst month phenprocoumon effectiveness stroke genotype-guided difference derivative effect value pharmacogenetic testing anticoagulant therapy netherland atrial fibrillation future schalekamp algorithm science testing utrecht pharmacogenomic country genotype-guided dosing review strategy thromboembolic events polymorphism information period evaluation variant pharmacogenetic-guided dosing cyp 2c genotypes carrier factor verhoef monitoring inr range outcome percentage percentage time vkorc 1 genotypes wild-type practice allele quality thromboembolic schie ratio eu-pact measurement evidence